Enfuvirtide: The first HIV fusion inhibitor

Adriano Lazzarin

Research output: Contribution to journalArticle

Abstract

Highly active antiretroviral therapy, a combination of antiretrovirals to treat HIV-infected individuals, may fail for a number of reasons, including the selection of genetic mutations which confer resistance to the antiretroviral drugs, and poor adherence or treatment discontinuation resulting from drug toxicity. Treatment-experienced patients, who have failed therapy owing to the emergence of drug-resistant virus, have a significant unmet medical need. Enfuvirtide (T-20), the first of a new class of antiretroviral agents known as HIV fusion inhibitors, has a unique mechanism of action involving disruption of HIV entry at the stage of membrane fusion. The potent antiviral activity and favourable safety and tolerability profile of enfuvirtide has been demonstrated in combination with other agents. Its novel mechanism of action offers a low potential for cross-resistance with conventional classes of antiretrovirals, and its extracellular distribution means that drug interactions and intracellular metabolic disturbances are unlikely. Targeting viral fusion or entry will hopefully provide respite for patients who have limited treatment options following the emergence of multi-drug resistance.

Original languageEnglish
Pages (from-to)453-464
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Volume6
Issue number3
DOIs
Publication statusPublished - Mar 2005

Fingerprint

HIV Fusion Inhibitors
HIV
Anti-Retroviral Agents
Membrane Fusion
Highly Active Antiretroviral Therapy
Multiple Drug Resistance
Therapeutics
Drug-Related Side Effects and Adverse Reactions
Drug Interactions
Pharmaceutical Preparations
Antiviral Agents
Viruses
Safety
Mutation
enfuvirtide

Keywords

  • Enfuvirtide
  • HIV
  • HIV fusion inhibitors
  • T-20

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Enfuvirtide : The first HIV fusion inhibitor. / Lazzarin, Adriano.

In: Expert Opinion on Pharmacotherapy, Vol. 6, No. 3, 03.2005, p. 453-464.

Research output: Contribution to journalArticle

Lazzarin, Adriano. / Enfuvirtide : The first HIV fusion inhibitor. In: Expert Opinion on Pharmacotherapy. 2005 ; Vol. 6, No. 3. pp. 453-464.
@article{9b2f4702158349daa27e28d4b58108b5,
title = "Enfuvirtide: The first HIV fusion inhibitor",
abstract = "Highly active antiretroviral therapy, a combination of antiretrovirals to treat HIV-infected individuals, may fail for a number of reasons, including the selection of genetic mutations which confer resistance to the antiretroviral drugs, and poor adherence or treatment discontinuation resulting from drug toxicity. Treatment-experienced patients, who have failed therapy owing to the emergence of drug-resistant virus, have a significant unmet medical need. Enfuvirtide (T-20), the first of a new class of antiretroviral agents known as HIV fusion inhibitors, has a unique mechanism of action involving disruption of HIV entry at the stage of membrane fusion. The potent antiviral activity and favourable safety and tolerability profile of enfuvirtide has been demonstrated in combination with other agents. Its novel mechanism of action offers a low potential for cross-resistance with conventional classes of antiretrovirals, and its extracellular distribution means that drug interactions and intracellular metabolic disturbances are unlikely. Targeting viral fusion or entry will hopefully provide respite for patients who have limited treatment options following the emergence of multi-drug resistance.",
keywords = "Enfuvirtide, HIV, HIV fusion inhibitors, T-20",
author = "Adriano Lazzarin",
year = "2005",
month = "3",
doi = "10.1517/14656566.6.3.453",
language = "English",
volume = "6",
pages = "453--464",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - Enfuvirtide

T2 - The first HIV fusion inhibitor

AU - Lazzarin, Adriano

PY - 2005/3

Y1 - 2005/3

N2 - Highly active antiretroviral therapy, a combination of antiretrovirals to treat HIV-infected individuals, may fail for a number of reasons, including the selection of genetic mutations which confer resistance to the antiretroviral drugs, and poor adherence or treatment discontinuation resulting from drug toxicity. Treatment-experienced patients, who have failed therapy owing to the emergence of drug-resistant virus, have a significant unmet medical need. Enfuvirtide (T-20), the first of a new class of antiretroviral agents known as HIV fusion inhibitors, has a unique mechanism of action involving disruption of HIV entry at the stage of membrane fusion. The potent antiviral activity and favourable safety and tolerability profile of enfuvirtide has been demonstrated in combination with other agents. Its novel mechanism of action offers a low potential for cross-resistance with conventional classes of antiretrovirals, and its extracellular distribution means that drug interactions and intracellular metabolic disturbances are unlikely. Targeting viral fusion or entry will hopefully provide respite for patients who have limited treatment options following the emergence of multi-drug resistance.

AB - Highly active antiretroviral therapy, a combination of antiretrovirals to treat HIV-infected individuals, may fail for a number of reasons, including the selection of genetic mutations which confer resistance to the antiretroviral drugs, and poor adherence or treatment discontinuation resulting from drug toxicity. Treatment-experienced patients, who have failed therapy owing to the emergence of drug-resistant virus, have a significant unmet medical need. Enfuvirtide (T-20), the first of a new class of antiretroviral agents known as HIV fusion inhibitors, has a unique mechanism of action involving disruption of HIV entry at the stage of membrane fusion. The potent antiviral activity and favourable safety and tolerability profile of enfuvirtide has been demonstrated in combination with other agents. Its novel mechanism of action offers a low potential for cross-resistance with conventional classes of antiretrovirals, and its extracellular distribution means that drug interactions and intracellular metabolic disturbances are unlikely. Targeting viral fusion or entry will hopefully provide respite for patients who have limited treatment options following the emergence of multi-drug resistance.

KW - Enfuvirtide

KW - HIV

KW - HIV fusion inhibitors

KW - T-20

UR - http://www.scopus.com/inward/record.url?scp=17144420144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144420144&partnerID=8YFLogxK

U2 - 10.1517/14656566.6.3.453

DO - 10.1517/14656566.6.3.453

M3 - Article

C2 - 15794736

AN - SCOPUS:17144420144

VL - 6

SP - 453

EP - 464

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 3

ER -